Search Results - "Krijgsman, O"

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma by Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J. B. A. G., Stretch, J., Ch’ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., Blank, C. U.

“…Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN (…”
Get full text

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors by Azimi, Alireza, Caramuta, Stefano, Seashore‐Ludlow, Brinton, Boström, Johan, Robinson, Jonathan L, Edfors, Fredrik, Tuominen, Rainer, Kemper, Kristel, Krijgsman, Oscar, Peeper, Daniel S, Nielsen, Jens, Hansson, Johan, Egyhazi Brage, Suzanne, Altun, Mikael, Uhlen, Mathias, Maddalo, Gianluca

“…Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of…”
Get full text

PRAME expression and clinical outcome of breast cancer by Epping, M T, Hart, A A M, Glas, A M, Krijgsman, O, Bernards, R

“…The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed…”
Get full text

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma by Theelen, W S M E, Krijgsman, O, Monkhorst, K, Kuilman, T, Peters, D D G C, Cornelissen, S, Ligtenberg, M A, Willems, S M, Blaauwgeers, J L G, van Noesel, C J M, Peeper, D S, van den Heuvel, M M, Schulze, K

“…The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in…”
Get full text

High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer by Belt, E. J. Th, te Velde, E. A., Krijgsman, O., Brosens, R. P. M., Tijssen, M., van Essen, H. F., Stockmann, H. B. A. C., Bril, H., Carvalho, B., Ylstra, B., Bonjer, H. J., Meijer, G. A.

“…Background Lymph node (LN) yield in colon cancer resection specimens is an important indicator of treatment quality and has especially in early-stage patients…”
Get full text

OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) by Blank, C.U., Rozeman, E.A., Menzies, A.M., van de Wiel, B.A., Adhikari, C., Sikorska, K., Krijgsman, O., Eriksson, H., Bierman, C., Grijpink-Ongering, L., Gonzalez, M., Broeks, A., Guminski, A.D., Spillane, A.J., Klop, W.M.C., Saw, R.P.M., Scolyer, R.A., van Akkooi, A.C.J., Hansson, J., Long, G.V.

Get full text

Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival by Kwakman, R, de Cuba, E M V, de Winter, J P, de Hingh, I H J T, Delis-van Diemen, P M, Tijssen, M, Rooimans, M A, Krijgsman, O, Carvalho, B, Peters, G J, Bonjer, H J, Meijer, G A, te Velde, E A

“…Background: Patients with peritoneal metastases (PMs) originating from colorectal carcinoma (CRC) are curatively treated by cytoreductive surgery (CRS) and…”
Get full text

PO-274 Tumour subtype-specific cells of origin of malignant mesothelioma by Vries, HI De, Song, JY, Bhaskaran, R, Krijgsman, O, Isogai, T, Innocenti, M, Berns, A

“…IntroductionMalignant Mesothelioma (MM) is an aggressive malignancy of the lining of the thoracic and peritoneal cavity. The primary cause is previous asbestos…”
Get full text

PO-512 Gene expression signature comprising distinct stromal and tumor-intrinsic signals predicts response to combined anti-PD1 and anti-CTLA4 checkpoint inhibition by Krijgsman, O, Kemper, K, Rozeman, E, Cornelissen-Steijger, P, Shahrabi, A, Haanen, J, Adams, D, Blank, C, Peeper, D

“…IntroductionInnovations in both targeted and immunotherapy (IT) of metastatic melanoma have led to improved responses in a considerable number of patients. For…”
Get full text

0063 Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients (PATH) with early stage breast cancer by Kunz, G, Dimpfl, T, Jakisch, C, Buttner, R, de Snoo, F, Krijgsman, O, van Lienen, E, Glas, A, Bender, R

Get full text

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial by Rozeman, Elisa A, Menzies, Alexander M, van Akkooi, Alexander C J, Adhikari, Chandra, Bierman, Carolien, van de Wiel, Bart A, Scolyer, Richard A, Krijgsman, Oscar, Sikorska, Karolina, Eriksson, Hanna, Broeks, Annegien, van Thienen, Johannes V, Guminski, Alexander D, Acosta, Alex Torres, ter Meulen, Sylvia, Koenen, Anne Miek, Bosch, Linda J W, Shannon, Kerwin, Pronk, Loes M, Gonzalez, Maria, Ch'ng, Sydney, Grijpink-Ongering, Lindsay G, Stretch, Jonathan, Heijmink, Stijn, van Tinteren, Harm, Haanen, John B A G, Nieweg, Omgo E, Klop, Willem M C, Zuur, Charlotte L, Saw, Robyn P M, van Houdt, Winan J, Peeper, Daniel S, Spillane, Andrew J, Hansson, Johan, Schumacher, Ton N, Long, Georgina V, Blank, Christian U

“…The outcome of patients with macroscopic stage III melanoma is poor. Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule…”
Get full text

LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial by Zuur, L., Vos, J.L., Elbers, J.B., Krijgsman, O., Qiao, X., van der Leun, A., Smit, L., van den Brekel, M.W., Tan, B., Jasperse, B., Vogel, W.V., Willems, S.M., Al-Mamgani, A., Peeper, D., Schumacher, T.N., Blank, C.U., de Boer, J.P., Haanen, J.B.A.G.

Get full text

LBA7518-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma by Rozeman, E A, Menzies, A M, Krijgsman, O, Hoefsmit, E P, van de Wiel, B A, Sikorska, K, Van, T M, Eriksson, H, Bierman, C, Gonzalez, M, Shannon, K, Broeks, A, Kerkhoven, R, Spillane, A J, Saw, R P, van Akkooi, A C J, Scolyer, R A, Hansson, J, Long, G V, Blank, C U

“…Abstract Background Primary analysis of the OpACIN-neo study testing 3 dosing schedules of neoadj IPI+NIVO identified 2 cycles IPI 1 mg/kg + NIVO 3 mg/kg…”
Get full text

LBA75 - 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma by Rozeman, E.A., Menzies, A.M., Krijgsman, O., Hoefsmit, E.P., van de Wiel, B.A., Sikorska, K., Van, T.M., Eriksson, H., Bierman, C., Gonzalez, M., Shannon, K., Broeks, A., Kerkhoven, R., Spillane, A.J., Saw, R.P., van Akkooi, A.C.J., Scolyer, R.A., Hansson, J., Long, G.V., Blank, C.U.

“…Primary analysis of the OpACIN-neo study testing 3 dosing schedules of neoadj IPI+NIVO identified 2 cycles IPI 1mg/kg + NIVO 3mg/kg (IPI1+NIVO3; arm B) as most…”
Get full text

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma by Rozeman, E.A., Menzies, A.M., Krijgsman, O., Hoefsmit, E.P., van de Wiel, B.A., Sikorska, K., Van, T.M., Eriksson, H., Bierman, C., Gonzalez, M., Shannon, K., Broeks, A., Kerkhoven, R., Spillane, A.J., Saw, R.P., van Akkooi, A.C.J., Scolyer, R.A., Hansson, J., Long, G.V., Blank, C.U.

Get full text

Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma by Rozeman, Elisa A., Reijers, Irene L.M., Hoefsmit, Esmée P, Sikorska, Karolina, Krijgsman, Oscar, Van De Wiel, Bart A., Dimitriadis, Petros, Eriksson, Hanna, Gonzalez, Maria, Grijpink-Ongering, Lindsay G, Kerkhoven, Ron M., Broeks, Annegien, Klop, Willem M.C., Spillane, Andrew, Saw, Robyn PM, Van Akkooi, Alexander Christopher Jonathan, Scolyer, Richard A., Menzies, Alexander M., Long, Georgina V., Blank, Christian U.

“…Abstract only 10015 Background: Early results of the OpACIN-neo study testing 3 different dosing schedules of neoadjuvant IPI + NIVO demonstrated that 2 cycles…”
Get full text

LBA330 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial) by Rozeman, E A, Sikorska, K, van de Wiel, B A, Fanchi, L F, Krijgsman, O, van Thienen, H V, Pronk, L M, Broeks, A, Grijpink-Ongering, L, Ter Meulen, S, Bruining, A, Klop, W M C, van Tinteren, H, Peeper, D, Haanen, J B A G, van Akkooi, A C J, Schumacher, T N, Blank, C U

Get full text

30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial) by Rozeman, E.A., Sikorska, K., van de Wiel, B.A., Fanchi, L.F., Krijgsman, O., van Thienen, H.V., Pronk, L.M., Broeks, A., Grijpink-Ongering, L., Ter Meulen, S., Bruining, A., Klop, W.M.C., van Tinteren, H., Peeper, D., Haanen, J.B.A.G., van Akkooi, A.C.J., Schumacher, T.N., Blank, C.U.

Get full text

LBA42OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) by Blank, C U, Rozeman, E A, Menzies, A M, van de Wiel, B A, Adhikari, C, Sikorska, K, Krijgsman, O, Eriksson, H, Bierman, C, Grijpink-Ongering, L, Gonzalez, M, Broeks, A, Guminski, A D, Spillane, A J, Klop, W M C, Saw, R P M, Scolyer, R A, van Akkooi, A C J, Hansson, J, Long, G V

Get full text

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles by Linn, SC, Severson, TM, Nevedomskaya, E, Peeters, J, van Rossum, A, Kuilman, T, Krijgsman, O, Goossens, I, Glas, A, Koornstra, R, Peeper, D, Wesseling, J, Simon, I, Wessels, L, Zwart, W

“…Abstract Background: The majority of breast cancer patients are diagnosed with ERα-positive breast cancer. Most ERα-positive patients are treated with adjuvant…”
Get full text